Carisma Tx Shows Initial Results from its Collaboration with Moderna; AstraZeneca Presents AZD6422’s Preclinical Development in Gastrointestinal Cancers and a Synergistic Combination of AZD074 with Enzalutamide in Prostate Cancer; SITC 2023 Analysis 1
SITC 2023 Analysis 1: Carisma Tx and AstraZeneca presented preclinical data from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.